OLUFUNKE ADEWUNMI: Open Payments
NPI 1942793773 · SMYRNA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,730 in 179 payments from 20 companies in 2025. Trend: 2023 $2,414 · 2024 $3,605 · 2025 $3,730
Food & beverage: $3,726Education: $5
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $664 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $461 |
| Axsome Therapeutics, Inc. | 12 | $411 |
| Vanda Pharmaceuticals Inc. | 13 | $371 |
| Neurocrine BioSciences, Inc. | 14 | $277 |
| Janssen Pharmaceuticals, Inc | 10 | $264 |
| Lundbeck LLC | 14 | $237 |
| Teva Pharmaceuticals USA, Inc. | 12 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $160 |
| ABBVIE INC. | 11 | $139 |
Products named: REXULTI, CAPLYTA, Auvelity, FANAPT, INGREZZA, TRINTELLIX, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across GA — which companies pay providers there.
